FBXO34

Gap: The endogenous substrate repertoire of human FBXO34-SCF remains largely undefined. HNRNPU is the only clearly supported human substrate in the retrieved mechanistic literature, while many high-throughput protein-binding partners have not been shown to be FBXO34-dependent ubiquitination substrates.

OPEN BIOLOGYCURATION MF_DARK

What is known: The review supports FBXO34 as an SCF substrate-recognition adaptor and accepts HNRNPU-linked ubiquitination/degradation as the best-supported human substrate example. The gap is which additional interactors, if any, are bona fide physiological substrates and whether the inferred SCF adaptor function has broader substrate-specific biological roles.

Significance: Substrate scope determines whether FBXO34 should receive only the generic ubiquitin-like ligase-substrate adaptor annotation or additional substrate/pathway-specific process annotations. It also determines whether current protein-binding annotations should remain non-core interactome noise or be converted into mechanistically supported substrate relationships.

What would resolve it: Endogenous FBXO34 knockout/rescue, substrate-trapping mutants, quantitative proteomics, ubiquitin-remnant profiling, and direct reconstitution of candidate ubiquitination reactions would distinguish degradative substrates from non-substrate interactors.

Provenance (the field's own admissions):

• "Across the retrieved literature, **hnRNP U** is the only clearly identified substrate/target of human FBXO34 with direct mechanistic support." — file:human/FBXO34/FBXO34-deep-research-falcon.md
• "direct biochemical details (e.g., linkage type, E2 usage, proteasome-inhibition rescue) were not captured in the available evidence snippets." — file:human/FBXO34/FBXO34-deep-research-falcon.md
• "broader roles in cell-cycle or disease biology remain plausible but underdefined." — file:human/FBXO34/FBXO34-deep-research-falcon.md

Gap: The relationship between FBXO34's human HNRNPU/HIV-latency function and the mouse oocyte cell-cycle phenotype remains unresolved. Mouse data suggest FBXO34 can influence meiotic G2/M transition, MPF/CCNB1 activity, spindle checkpoint behavior, and anaphase entry, but the direct substrate(s) and relevance to human FBXO34 biology are unknown.

OPEN BIOLOGYCURATION BP_DARK

What is known: The review treats mouse oocyte findings as orthology-based, hypothesis- generating evidence, not as a direct human core biological-process annotation. HNRNPU degradation is the supported human pathway-level example.

Significance: Resolving this gap would determine whether FBXO34 should be annotated to cell-cycle or meiotic processes in human, or whether those findings should remain non-human context while the human review stays focused on HNRNPU-linked post-transcriptional regulation of HIV latency.

What would resolve it: Test FBXO34 perturbation in human germ-cell or cell-cycle models, identify FBXO34-dependent ubiquitination substrates in those systems, and ask whether CCNB1/MPF phenotypes can be rescued by substrate-specific manipulation.

Provenance (the field's own admissions):

• "mouse oocyte phenotypes indicate FBXO34 can influence meiosis and checkpoint progression, but the direct substrate(s) in that setting are unknown, and the extent to which this translates to human tissues is not resolved by the retrieved evidence." — file:human/FBXO34/FBXO34-deep-research-falcon.md
• "Supports conserved biology for FBXO34 as an **SCF-type F-box regulator of cell-cycle control**, likely acting upstream of **CCNB1/CDK1/MPF** and checkpoint progression." — file:human/FBXO34/FBXO34-deep-research-falcon.md
• "This is informative for function but is **not direct human evidence**." — file:human/FBXO34/FBXO34-deep-research-falcon.md

Gap: Human FBXO34 subcellular localization remains experimentally underdefined. Mouse oocyte data suggest nuclear and F-actin-associated localization, but direct human localization evidence, and the compartment in which FBXO34 acts on HNRNPU or other substrates, were not recovered.

OPEN BIOLOGYCURATION CC_DARK

What is known: The review supports intracellular SCF-substrate-adaptor activity but does not assign a core cellular component beyond SCF complex membership. Mouse oocyte localization is treated as a hypothesis for human work, not a direct human cellular-component annotation.

Significance: Localization would refine where FBXO34 performs substrate recognition and would help separate generic SCF complex membership from human nuclear, cytoplasmic, RNP-associated, or cytoskeletal substrate contexts.

What would resolve it: Endogenous tagging or validated antibodies should map FBXO34 localization in human cells under basal, HIV-latency, proteasome-inhibited, and cell-cycle conditions, paired with substrate colocalization and compartment-specific degradation assays.

Provenance (the field's own admissions):

• "Direct **human subcellular localization** data for FBXO34 was not recovered from the accessible text snippets; localization statements come from mouse oocytes and should be treated as context rather than definitive for human somatic cells." — file:human/FBXO34/FBXO34-deep-research-falcon.md
• "In mouse oocytes, FBXO34 was reported to localize mainly in the **nucleus** and to **colocalize with F-actin** during meiotic maturation." — file:human/FBXO34/FBXO34-deep-research-falcon.md